DermTech, a provider in precision dermatology enabled by a non-invasive skin genomics platform, announced that U.S. General Services Administration has recommended the company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA).
This coverage recommendation makes the foundational assay of the DMT available to the VHA’s over 9 million enrolled Veterans. The DMT is a non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (NPV), according to the company.
The VHA provides care at 1,298 healthcare facilities across the United States.
“We’re honored to join the VHA in bringing our non-invasive melanoma test to America’s Veterans,” says Dan Visage, senior vice president of payor access, DermTech. “The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. We look forward to teaming up with the VHA to make our test widely available to its beneficiaries in the coming months.”
DermTech’s total covered lives in the U.S. are now approximately 124 million, which includes 68 million for Medicare/Medicare Advantage and 56 million for commercial and governmental payers. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments.
Featured image: Melanoma
